Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. CERE.NASDAQ

Cerevel Therapeutics Holdings Inc (CERE NASDAQ) stock market data APIs

$44.42 -0.2(-0.4%) as of July 26, 2024
Price chart is built with Anychart

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Cerevel Therapeutics Holdings Inc Financial Data Overview

44.62
44.42
-
44.66
44.375
19.59-44.66
8 089 M
182 M
0
1.407
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CERE',
Type: 'Common Stock',
Name: 'Cerevel Therapeutics Holdings Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00VCYVLH4',
ISIN: NULL,
CUSIP: NULL,
CIK: '1805387',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2020-10-28',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Cerevel Therapeutics Holdings Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -484 523 008
  • Earnings Per Share -2.73
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Cerevel Therapeutics Holdings Inc Earnings via APIs

  • Latest Release 2024-07-31
  • EPS/Forecast -0.61

Get Cerevel Therapeutics Holdings Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Cerevel Therapeutics Holdings Inc latest news via APIs

CERE Stock Earnings: Cerevel Therapeutics Hldg Misses EPS for Q2 2024

CERE stock results show that Cerevel Therapeutics Hldg missed analyst estimates for earnings per share the second quarter of 2024.

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from...
Do you have any questions?
support@eodhistoricaldata.com